We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

CST Expands Partnership with Bio-Rad

CST Expands Partnership with Bio-Rad

CST Expands Partnership with Bio-Rad

CST Expands Partnership with Bio-Rad

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "CST Expands Partnership with Bio-Rad "

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Cell Signaling Technology, Inc. (CST), has announced that it has entered into a new partnership agreement with Bio-Rad Laboratories, Inc.

Under the agreement, CST will develop antibodies for kinase activation and protein phosphorylation assays that will be commercialized in Bio-Rad's multiplex bead-based assays for the Bio-Plex® suspension array system.

CST's scientific and technical expertise will be leveraged to develop a broader array of antibodies for Bio-Rad's Bio-Plex® platform, enabling multiplexed measurement of phosphoproteins and signaling pathways.

Bio-Plex® phosphoprotein assays are optimized for simultaneous assessment of kinase and signaling protein activation states and provide critical tools for disease research and drug development.

Given the complexity of cellular signaling and the diversity of mechanistic abnormalities underlying disease, Bio-Plex® multiplexed phosphoprotein assays can facilitate the understanding of disease and the development of more effective targeted therapeutic strategies.

"Our partnership with Bio-Rad in the past has enabled CST to combine our antibody expertise with Bio-Rad's strength in multiplexed assay technologies," said Christopher Bunker, CST's Director of Business Development.

"Bio-Plex phosphoprotein assays built with CST antibody content provide the means for rigorous parallel analysis of signal transduction pathways."

"Advances in cellular signaling research will have a great impact both in our understanding of fundamental biological processes and in advancing the treatment of disease," said Bio-Rad Vice President and Group Manager, Life Science Group, Brad Crutchfield.

"Together, CST and Bio-Rad can provide more quickly a broader array of tools for kinase and signal transduction research."